SK Capital Partners is an investment firm focused on the specialty materials, chemicals, and life sciences sectors. They pursue buyouts, recapitalizations, and growth equity investments, and buy-and-hold strategies with management teams to transform businesses using a disciplined approach and active engagement to drive positive transformational change.
This page’s information is derived from self-reported data provided by employees, users of Zippia, and third parties; thus, it may change at any time.
SK Capital Partners is a private investment firm.
SK Capital Partners is an investment firm founded in 2007 that invests across multiple sectors, from specialty chemicals and pharmaceuticals to real estate. Operating out of New York City, they have made over 30 investments since inception, boasting an excellent management team. To properly oversee their portfolio of assets, they use several products, including fund manager platforms, fund administrator platforms, and private equity databases.
SK Capital Partners has invested in several life sciences technology and healthcare firms and acquired numerous semiconductor and materials-focused firms. Furthermore, their employees work across different locations worldwide and provide advisory services to clients.
SK Capital Partners manages assets worth over $2 billion for 25 client accounts, registered as an investment adviser with the Securities and Exchange Commission. They specialize in asset management for pooled investment vehicles but do not provide financial planning services directly.
Recently, SKCP Catalyst Fund II closed with an oversubscription of committed capital of $800 million and will focus on buyout investments requiring initial committed equity capital of $100 million or less; its typical focus areas include control buyouts and recapitalizations.
SK Capital Partners also operates as an investor in secondaries, giving it access to an exclusive deal flow of potential buyers without revealing its identity.
SK Capital Partners is a private equity firm dedicated to supporting companies’ expansion by offering strategic guidance and financial resources. Specializing in mature and middle-market companies throughout North America, this private equity firm manages two funds: Flagship and Catalyst – with Flagship catering more towards larger firms while Catalyst favors lower middle-market businesses – both controlled by an expert team of five Managing Directors with extensive industry, operational, and investment experience.
SK Capital Partners invests in companies.
SK Capital Partners is a private investment firm that invests across various industries. It prioritizes businesses with solid growth prospects and the potential for significant business improvement and will consider any transaction, including buyouts, recapitalization, and growth equity financings.
SK Capital Partners oversees over $3 billion in assets under management. Their diverse investment portfolio spans multiple sectors, emphasizing specialty materials, ingredients, and life sciences investments. Their highly experienced team of professionals boasting extensive industry, operating, and investment experience helps transform businesses into higher-performing organizations with improved strategic positioning and growth, increased profitability, and decreased operating risk.
SK Capital Partners not only provides capital but also strategic advisory services. As a SEBI Registered Category I Merchant Banker, they specialize in investment banking, financial advisory services, and debt capital raising for institutions, corporates, Promoters, and high net worth individuals in India and worldwide. Headquartered in Mumbai.
Funds advised by SK Capital Partners LP (“SK Capital”) and Edgewater Capital Partners, LP (“Edgewater”) have successfully acquired Saint-Gobain S.A.’s scintillation and photonic crystal business, later known as Luxium Solutions upon its renaming in December 2022. The acquisition was funded with debt and equity provided by both firms.
This firm has invested in numerous small and mid-sized businesses, possessing an in-depth knowledge of their industries. Their experience with operationally focused middle market private equity investing has allowed them to deliver solid returns for investors. In contrast, their focus on building strong partnerships with management teams will enable them to create value within their portfolio companies.
SK Capital Partners has an impressive track record in healthcare sectors, making them one of the world’s premier investors. Their diverse private equity funds portfolio has attracted over $7.8B in total equity commitments; its healthcare investments include purchasing numerous providers and companies in this industry and multiple acquisitions within the pharmaceutical, biotechnology, and medical devices sectors.
SK Capital Partners is based in New York.
SK Capital Partners of New York City invests in mature middle-market companies in North America with profits that present significant opportunities for improvement. Transactions typically include buyout investments, recapitalization, and growth equity financings; markets targeted include specialty materials, chemicals, and healthcare; businesses usually generate at least $50 million in revenue and $100 million in EBITDA before being considered by SK Capital Partners; they may also consider corporate carve-outs.
SK Capital Partners employs a systematic sector-focused approach to value creation, drawing upon extensive industry, operating, and investment experience to transform businesses into higher-performing organizations with enhanced strategic positioning, growth, and profitability, reduced managing risk, and improved performance. Their team collaborates closely with management teams to identify transformational growth opportunities and capitalize on them effectively.
SK Capital Partners, L. P. is an advisory firm in New York City that manages $4.69 billion across 25 client accounts and provides portfolio management for pooled investment vehicles. However, individual clients do not offer financial planning services to SK Capital Partners as its major clients are pooled investment vehicles, with 92% of total assets belonging to foreign persons or entities; they have also advised additional private funds since 2015. SK Capital Partners was founded in 2015 and began business activities.
SK Capital Partners has 30 employees.
SK Capital Partners is a private investment firm of 30 employees in New York with additional locations throughout the US. Their employees boast highly specialized skills and experience and enjoy an attractive salary and benefits package; plus, they make for a positive work culture at this vibrant company.
Since 2007, SK Capital Partners has invested in specialty materials, ingredients, and life sciences sectors using a disciplined investment approach with small, medium, and large companies to turn them into high-performing enterprises. Flagship and Catalyst funds invest in companies at various stages in their life cycles – small businesses through to lower middle market investments.
Since its establishment, SK Capital has completed over 100 transactions and exited various investments, such as those with Neckermann (a German mail-order retailer) and Bruegger’s Bagels. Other notable companies in its portfolio are Polestar UK Print, Britton Group, Contessa Premium Foods, and Vitro America; in total, 33 acquisitions with over 50,000 employees have also been completed by this organization.
Recently, SK Capital invested in the plastics and specialty chemicals industries via their Valentus Specialty Chemicals platform. This move fits with their commitment to supporting companies that uphold strong environmental, social, and governance practices; additionally, their management team boasts extensive expertise in specialty materials packaging industries.
Valentus’ investment was enabled by acquiring Canlak Inc., an industrial coatings manufacturer. This transaction constitutes a substantial addition to Valentus and should lead to synergies across operations, sales, marketing, and finance – the combined company will be based out of Schenectady, N.Y., with 30 manufacturing locations worldwide.
In 2022, SK Capital announced its acquisition of Addivant, a global supplier of additives and process solutions serving numerous industries such as plastics, rubber, fuel lubricants, oilfield, and pharmaceutical (API) markets. The deal will create a leading player in global performance additives with backward integration into crucial chemical intermediates backed by funds advised by both SK Capital and HSBC Securities (USA) Inc.; Latham & Watkins LLP served as legal advisor for this transaction while Credit Agricole Italia SpA and Intesa Sanpaolo SpA served as arrangers/bookrunners respectively for both transactions.
